AFFITOPE® AT04 (licensed to Frontier Biotech)
Hypercholesterolemia
Phase 1Active
Key Facts
About AFFiRiS
AFFiRiS is an Austrian biotechnology company pioneering a vaccine-like immunotherapy platform, AFFITOME®, to treat chronic diseases by targeting pathological proteins. Its most advanced programs target alpha-synuclein for Parkinson's disease and PCSK9 for hypercholesterolemia, with multiple assets having reached Phase 1 clinical trials. The company operates as a private entity, advancing its pipeline through strategic partnerships and out-licensing deals, such as the acquisition of its alpha-synuclein programs by AC Immune in 2021.
View full company profileTherapeutic Areas
Other Hypercholesterolemia Drugs
| Drug | Company | Phase |
|---|---|---|
| VXX-401 | Vaxxinity | Phase 1 |
| Atorvastatin Oral Liquid Suspension | CMP Pharma | Approved |
| AQR-008 | Aqur Biosciences | Pre-clinical |
| Leqvio® (inclisiran) | Novartis | Approved |
| MK-0616 | Merck | Phase 3 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase III |
| IBI-306 | Innovent Biologics | NDA Submitted |
| Inusiran (AK102) | Akeso | Approved |
| Obicetrapib + Ezetimibe FDC | NewAmsterdam Pharma Company | Phase 3 |